ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia

Autor:	Lioba Schönfeld, Jenny Rinke, Anna Hinze, Saskia N. Nagel, Vivien Schäfer, Thomas Schenk, Christian Fabisch, Tim H. Brümmendorf, Andreas Burchert, Philipp le Coutre, Stefan W. Krause, Susanne Saussele, Fatemeh Safizadeh, Markus Pfirrmann, Andreas Hochhaus, Thomas Ernst
Rok vydání:	2022
Předmět:	Repressor Proteins Cancer Research Pyrimidines Oncology Leukemia Myelogenous Chronic BCR-ABL Positive Mutation Fusion Proteins bcr-abl Humans Hematology Protein Kinase Inhibitors
Zdroj:	Leukemia : normal and malignant hemopoiesis ; a peer-reviewed journal 36(9), 2242-2249 (2022). doi:10.1038/s41375-022-01648-4
ISSN:	1476-5551 0887-6924
DOI:	10.1038/s41375-022-01648-4
Popis:	Leukemia : normal and malignant hemopoiesis ; a peer-reviewed journal 36(9), 2242-2249 (2022). doi:10.1038/s41375-022-01648-4 Published by Springer Nature, London
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07975a8a3d7b6b8e124f29ead343792b https://doi.org/10.1038/s41375-022-01648-4 Zobrazit plný text záznamu Full text from SpringerLink